Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma

Iliev, Milko E; Domig, Diego; Wolf-Schnurrbursch, Ute; Wolf, Sebastián; Sarra, Gian-Marco

doi:10.1016/j.ajo.2006.06.066

Cited by 234 publications

(200 citation statements)

References 7 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…23,24 In this study, no intraoperative bleeding complications were recorded. However, non-sight threatening hyphema was a significant complication associated with bevacizumab treatment of NVG.…”

Section: Discussionmentioning

confidence: 99%

“…Case series and retrospective studies have reported only short-term reduction in neovascularization, inflammation and IOP in eyes receiving anti-VEGF agents. 24,28,30,33,36,[42][43][44][45] A systematic review of literature in 2013 concluded that no compelling evidence exists from which reliable conclusions could be drawn comparing the effects of anti-VEGF agents either alone or as an adjunctive modality to other forms of treatment but no anti-VEGF agents in NVG. 46 The review identified two RCTs evaluating intravitreal bevacizumab injection in NVG.…”

Section: Discussionmentioning

confidence: 99%

“…[17][18][19][20][21] The outcomes of off-label treatment of NVG with intravitreal bevacizumab have been reported. [22][23][24][25][26][27][28][29][30] We have previously published a retrospective interventional case series of NVG eyes describing the natural history of NVG treated with intravitreal bevacizumab. 22 However, conclusions regarding the exact role, efficacy, and drawbacks of intravitreal bevacizumab injection in eyes with NVG could not be drawn, since no comparison to eyes that did not receive this method of treatment was performed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Olmos

Sayed

Moraczewski

et al. 2015

Eye

View full text Add to dashboard Cite

Aims To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP).Results At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean ± SD) was 43.1 ± 13.0 mm Hg in the non-bevacizumab group and 40.8 ± 11.5 mm Hg in the bevacizumab group. IOP (mean ± SD) decreased to 18.3 ± 13.8 mm Hg in the nonbevacizumab group and 15.3 ± 8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (Po0.001) in bevacizumab treated NVG eyes. Conclusions Although bevacizumab delayed the need for glaucoma surgery, PRP was the most important factor that reduced the need for surgery. Vision and IOP in eyes with NVG treated with bevacizumab showed no long-term differences when compared with eyes that were not treated with bevacizumab. Thus, intravitreal bevacizumab serves as an effective temporizing treatment, but is not a replacement for close monitoring and definitive treatment of NVG. PRP remains the treatment modality that affects the course of NVG in terms of decreasing the need for surgery to control IOP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Olmos

Sayed

Moraczewski

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…It is also effective in reducing intraocular inflammation and pain and in few reports IOP lowering has been noted in the open angle stage. 23 Intracameral injection of Bevacizumab may provide additional strategy for treating rubeosis iridis in NVG. 20 Bevacizumab is well tolerated, effectively stabilizes NVI, and controls IOP when used alone and at an early open angle stage of NVG.…”

Section: Medical Management Of Nvgmentioning

confidence: 99%

Neovascular Glaucoma – A Review

Sharma¹

2016

DJO

View full text Add to dashboard Cite

show abstract

“…Entretanto, em casos mais avançados, com formação de sinéquias anteriores extensas, essa hipótese isoladamente não explica os resultados observados (55) . Iliev et al (56) descreveram uma série de 6 casos de glaucoma neovascular secundário à oclusão da veia central da retina com pressão intra-ocular muito elevada, sintomática e refratária ao tratamento clínico. Todos foram tratados com 1,25 mg de Bevacizumab intravítreo, o que resultou em regressão dos neovasos e melhora dos sintomas após 48h.…”

Section: Antivegf No Glaucoma Neovascularunclassified

Antiangiogênicos no glaucoma

Lucena¹,

Yamane²

2008

Rev. bras.oftalmol.

View full text Add to dashboard Cite

RESUMOA angiogênese é um processo complexo que resulta na formação de novos vasos sangüíneos. Ocorre tanto em situações fisiológicas quanto patológicas e está envolvida com várias patologias oculares. Dentre os mediadores químicos da angiogênese, o fator de crescimento do endotélio vascular (VEGF) é reconhecido como um dos mais importantes. Nos últimos anos, agentes antiVEGF foram introduzidos para o tratamento de neovascularizações do segmento posterior com resultados muito positivos. Alguns autores demonstraram benefícios do uso dessas substâncias no controle do glaucoma em situações específicas.

show abstract

Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma

Cited by 234 publications

References 7 publications

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Neovascular Glaucoma – A Review

Antiangiogênicos no glaucoma

Contact Info

Product

Resources

About